HUMA

0.82

3.24% -0.0275

Handel nachbörslich: .83 0.01 +1.22%

Humacyte Inc (HUMA)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt HUMA? Forum Prognose

Schlusskurs vom Vortag:

$0.8475

Offen:

$0.82

24-Stunden-Volumen:

3.46M

Relative Volume:

0.52

Marktkapitalisierung:

$182.06M

Einnahmen:

$2.04M

Nettoeinkommen (Verlust:

$-43.21M

KGV:

-3.9671

EPS:

-0.2067

Netto-Cashflow:

$-105.93M

1W Leistung:

+16.33%

1M Leistung:

+21.37%

6M Leistung:

-51.48%

1J Leistung:

-42.66%

1-Tages-Spanne:

$0.795

$0.8374

1-Wochen-Bereich:

$0.6765

$0.8511

52-Wochen-Spanne:

$0.5469

$2.93

Humacyte Inc Stock (HUMA) Company Profile

Firmenname

Humacyte Inc

Sektor

Healthcare (1108)

Branche

Biotechnology (620)

Telefon

919-313-9633

Adresse

2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM

Mitarbeiter

184

Twitter

Nächster Verdiensttermin

2026-05-12

Neueste SEC-Einreichungen

HUMA's Discussions on Twitter

Compare HUMA vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
HUMA Humacyte Inc	0.82	188.16M	2.04M	-43.21M	-105.93M	-0.2067
VRTX Vertex Pharmaceuticals Inc	423.24	109.41B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	686.36	76.72B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	776.02	48.20B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.19	40.31B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	290.80	33.13B	5.36B	287.73M	924.18M	2.5229

Humacyte Inc Stock (HUMA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-08-27	Eingeleitet	Barclays	Overweight
2025-05-14	Fortgesetzt	H.C. Wainwright	Buy
2024-12-20	Bestätigt	H.C. Wainwright	Buy
2023-12-11	Eingeleitet	H.C. Wainwright	Buy
2023-08-14	Hochstufung	Piper Sandler	Underweight → Neutral
2023-06-22	Eingeleitet	Cantor Fitzgerald	Overweight
2022-05-16	Herabstufung	Piper Sandler	Overweight → Underweight
2021-10-29	Eingeleitet	Cowen	Outperform
2021-09-24	Eingeleitet	Oppenheimer	Outperform
2021-09-22	Eingeleitet	BTIG Research	Buy
2021-09-16	Eingeleitet	Piper Sandler	Overweight

Alle ansehen

Humacyte Inc Aktie (HUMA) Neueste Nachrichten

04:33 AM

Humacyte regains ex-US rights to Symvess from Fresenius Medical Care - MSN

04:33 AM

11:14 AM

H.C. Wainwright Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $3 - Moomoo

11:14 AM

08:22 AM

Humacyte stock price target reiterated at $3 by H.C. Wainwright - Investing.com Canada

08:22 AM

07:10 AM

Barclays Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $1.5 - Moomoo

07:10 AM

01:22 AM

Humacyte Highlights Dialysis Access Data; Women Show Strong ATEV Edge, V012 Results Due in June - Yahoo Finance

01:22 AM

Apr 28, 2026

Humacyte (HUMA) price target decreased by 31.82% to 5.46 - MSN

Apr 28, 2026

TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $1 - Moomoo

Apr 28, 2026

Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026 - The Manila Times

Apr 27, 2026

Humacyte webcast tackles dialysis access with Phase 3 results due - Stock Titan

Apr 27, 2026

Humacyte Expands Commercial and Business Development Opportunities through Realignment of Ex-U.S. Rights to Symvess - marketscreener.com

Apr 27, 2026

Humacyte (HUMA) takes ex-U.S. Symvess control as Fresenius retains 8.4% stake - Stock Titan

Apr 27, 2026

Apr 25, 2026

Humacyte Stock (HUMA) Opinions on Symvess Rights Realignment - Quiver Quantitative

Apr 25, 2026

Humacyte regains ex-U.S. rights to Symvess from Fresenius By Investing.com - Investing.com Australia

Apr 25, 2026

Apr 24, 2026

Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc.HUMA - PR Newswire

Apr 24, 2026